Table 1.

Baseline characteristics of cohort grouped by creatinine clearance quintile

Variable	Entire cohort	Creatinine clearance quintiles (ml/min/1.73 m2)					Pa
		1	2	3	4	5
		(< 23)	(23 to <29)	(29 to <5)	(35 to < 43)	(≥43)
Age (y) (SD)	58 (12)	57 (11)	57 (12)	61 (12)	56 (14)	61 (11)	0.06
Female gender (%)	35	37	35	40	31	33	0.9
Diabetes (%)	32	33	35	28	42	21	0.1
Smokers (%)	54	49	53	62	52	54	0.7
Renal diagnosis (%)
diabetic nephropathy	21	25	22	19	22	17	0.8
hypertension	16	13	17	23	12	21	0.4
glomerulonephropathy	8	6	7	6	13	6	0.4
polycystic kidney disease	7	11	8	4	7	3	0.4
History of cardiovascular disease (%)b	29	14	21	36	28	17	0.04
Systolic BP (mmHg) (SD)	140 (22)	140 (23)	138 (21)	144 (24)	141 (22)	139 (21)	0.6
Diastolic BP (mmHg) (SD)	79 (11)	78 (9)	78 (11)	77 (12)	81 (10)	79 (10)	0.4
Serum albumin (g/L) (SD)	38 (4)	38 (4)	38 (4)	38 (5)	39 (4)	39 (4)	0.5
Proteinuria (g/day), median (IQR)	1.0 (0.3 to 2.5)	1.2 (0.4 to 2.3)	1.1 (0.3 to 2.7)	1.0 (0.4 to 2.6)	0.8 (0.2 to 2.6)	0.6 (0.2 to 2.3)	0.4
Hemoglobin (g/L) (SD)	126 (17)	119 (17)	122 (16)	124 (14)	129 (17)	132 (16)	<0.001
Serum calcium (mmol/L) (SD)	2.3 (0.1)	2.29 (0.16)	2.26 (0.14)	2.33 (0.14)	2.32 (0.12)	2.37 (0.15)	0.01
Serum phosphate (mmol/L) (SD)	1.2 (0.3)	1.37 (0.33)	1.25 (0.27)	1.16 (0.24)	1.18 (0.29)	1.11 (0.20)	<0.001
PTH (LN pmol/L) (SD)	3.6 (1.4)	3.9 (1.5)	3.6 (1.5)	3.6 (1.4)	3.6 (1.4)	3.5 (1.9)	0.6
Lipids (mmol/L) (SD)
total cholesterol	5.2 (1.2)	5.0 (1.2)	5.1 (1.2)	5.0 (1.1)	5.2 (1.3)	5.3 (1.1)	0.6
LDL	3.1 (1.1)	3.2 (1.2)	2.9 (1.0)	3.1 (1.0)	3.1 (1.1)	3.1 (1.0)	0.6
HDL	1.2 (0.4)	1.1 (0.4)	1.2 (0.4)	1.2 (0.4)	1.2 (0.4)	1.2 (0.4)	0.2
Triglycerides	2.4 (1.6)	2.3 (2.0)	2.5 (1.5)	2.3 (1.8)	2.4 (1.4)	2.3 (1.6)	0.9
Medications (%)
ACEIc or ARBd	46	44	43	43	55	46	0.6
diuretic	61	46	40	43	40	27	0.2
calcium blocker	38	41	44	38	36	36	0.5
beta blocker	23	21	29	30	16	19	0.2
HMG-CoA reductase inhibitors	27	30	29	30	22	32	0.8
fibric acid derivatives	6	8	10	4	4	3	0.4
phosphate binders	25	27	28	24	22	21	0.9
vitamin D3	12	22	17	8	9	3	0.007
ASA	20	16	28	19	21	17	0.5
erythropoietin	9	13	11	6	0	0	0.03
Median number of plaque measurements (IQR)e	3 (3 to 5)	3 (3 to 5)	3 (3 to 4)	3 (3 to 4)	3 (3 to 5)	3 (3 to 5)	0.06
Median follow-up, months (IQR)	13 (11 to 24)	13 (11 to 23)	12 (11 to 22)	12 (11 to 19)	18 (12 to 26)	13 (11 to 25)	0.07
Median plaque area, mm2 (IQR)	23 (1 to 84)	32 (0 to 84)	16 (0 to 75)	39 (8 to 141)	20 (0 to 88)	19 (2 to 51)	0.08
Median rate of plaque growth, mm2/yr (IQR)	3.0 (0 to 14)	0.4 (to 2 to 7)	1.0 (0 to 11)	6.0 (0 to 20)	3.9 (0 to 15)	5 (0 to 18)	0.02

^aComparison between quintiles using ANOVA for normally distributed variables, Kruskal-Wallis H test for non-normally distributed measures, and χ²test for categorical values.

^bDocumented prior myocardial infarction, ischemic stroke or peripheral arterial disease.

^cAngiotensin converting enzyme inhibitor.

^dAngiotensin II receptor blocker.

^eIQR, interquartile range.